Lymphoma/CLL Specialist @UofUHealth @huntsmancancer | My opinions are my own |
Joined August 2018
- Tweets 121
- Following 436
- Followers 218
- Likes 921
2 Photos and videos
Had an incredible time filming and participating in this fun discussion with some amazing CLL docs. Check it out!
Feb 12
How is the CLL treatment landscape shifting? Join experts to explore BTK and BCL2 inhibitor sequencing, MRD-guided strategies, and the role of pirtobrutinib.
Watch the full series: hubs.li/Q042LWcl0
@ErmannMD @UofUHealth @huntsmancancer @JavierPinillaMD @MoffittNews @mshadman @fredhutch
89
Daniel A. Ermann, MD retweeted
3 Mar 2025
Dr. @StevenBairMD @CULymphoma contributed to a multicenter study published in @Haematologica about real-world outcomes of lonca in R/R DLBCL. pubmed.ncbi.nlm.nih.gov/3954… #lymsm
4
11
753
Daniel A. Ermann, MD retweeted
3 Mar 2025
RW lonca R/R DLBCL outcomes:
- 187 pts, 17% bulky, 22% HGBL, 60% prior CAR
- ORR 32%, CR 14% (woof), no diff in outcomes if prior CAR
- mEFS 2.1 mos, mOS 4.6 mos
Dismal outcomes outside of trial setting. #lymsm
pubmed.ncbi.nlm.nih.gov/3954…
3
6
21
2,081
Daniel A. Ermann, MD retweeted
25 Feb 2025
Mosun-pola-CHP vs pola-R-CHP 1L DLBCL
- 62 pts
- mosun arm: CR 73%, 2-yr PFS 71%
- pola-R-CHP: CR 77%, 2-yr PFS 82%
- more tx d/c in mosun arm
No sig benefit of mosun-pola-CHP. #lymsm
ashpublications.org/bloodadv…
6
12
32
4,665
Daniel A. Ermann, MD retweeted
20 Feb 2025
We are excited to have @ErmannMD from @UofUHealth @huntsmancancer, @poh_christina from @fredhutch @UWMedicine and @TravisWiliamsDO from @stlukeshealth talking about #lymphoma at #BTFHemBreast25 in Boise! Join us: education.binayfoundation.or… #MedTwitter #MedX #MedEd
2
5
828
Daniel A. Ermann, MD retweeted
9 Dec 2024
Pola outcomes by Hans COO @Eddie_Cliff @dgermain21 #ASH24
- >700 pts in 1L & R/R cohorts
- non-GC ORR/CR significantly better in R/R (60% vs 36%), but not 1L cohort
- non-GCC PFS (not OS) better in R/R, not 1L
- PFS better for non-GC if pola used after (not before) CAR
1/ #lymsm
3
15
42
7,913
Daniel A. Ermann, MD retweeted
10 Dec 2024
WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. @timfenske #ASH24
2
28
93
5,945
Daniel A. Ermann, MD retweeted
19 Nov 2024
Our @CULymphoma faculty Dr. @StevenBairMD contributed to a multicenter real-world study of loncastuximab in R/R DLBCL in @Haematologica. Outcomes were inferior to those described in clinical trials, with median EFS and OS of 2.1 and 4.6 months. #lymsm
pubmed.ncbi.nlm.nih.gov/3954…
1
3
14
1,014
Daniel A. Ermann, MD retweeted
18 Nov 2024
Golcadomide (CELMoD) RCHOP 1L LBCL @Lymphoma_Doc #ASH24:
- randomized 0.2 vs 0.4 mg in dose expansion
- 1-yr PFS 85% at 0.4 mg (77% at 0.2)
- 90% EOT MRD- at 0.4 (73% at 0.2)
- better EOT MRD- with 0.4 mg across high-risk genetics
GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm
1
8
27
2,869
In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: nej.md/3A00MYS
ALT Original Article Nivolumab AVD in Advanced-Stage Classic Hodgkin’s Lymphoma A graph of progression-free survival
1
47
128
28,340
Daniel A. Ermann, MD retweeted
11 Oct 2024
Congratulations to the 2024 Young Hematology Scholar Awardees! 🏆🩸Thank you for sharing your groundbreaking work and presenting at the #HemeSummit24 this weekend in Nashville! @AkritiC54828 @EmperorBlackMD @FahminB_MDPhD @LopedotePaolo @HannahGoulart @KLChohan @MDAndersonNews @MCIStrong @UICancerCenter @DukeMedSchool @COH_RadOnc @UofUHealth @NorthwesternMed
Read more: binayfoundation.org/hematolo…
#YoungHematologyScholars #HemOnc #Oncology #cancer #medx #meded #OncoDaily
4
7
31
7,152
Daniel A. Ermann, MD retweeted
8 Oct 2024
Interested in joining an awesome and collaborative Lymphoma team as a pharmacist? We're hiring! See attached posting.
@TischCancer
@IcahnMountSinai
careers.accp.com/job/2155343…
2
6
397
Daniel A. Ermann, MD retweeted
22 Aug 2024
New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer
1
2
156
Daniel A. Ermann, MD retweeted
3 Aug 2024
New frontiers in r/r CLL: Dr. Daniel Ermann explores pirtobrutinib and CAR-T therapy. Key points on efficacy, toxicity, and patient selection. How will these options impact your treatment decisions? bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer
1
1
189
Daniel A. Ermann, MD retweeted
25 Jul 2024
New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer
2
1
270
Daniel A. Ermann, MD retweeted
29 Jul 2024
Important new #CLL news
PFS advantage for Acala-Ven /-Obin vs ICT in 1L CLL.
astrazeneca.com/media-centre…
22
60
11,381
Daniel A. Ermann, MD retweeted
22 Jul 2024
Healthcare providers: Our partner, Patient Empowerment Network (PEN), is hosting a webinar addressing optimizing CLL care, with @ChangMDPhD of Emory Healthcare and @ErmannMD of Huntsman Cancer Institute, on Aug. 13 at 1pm ET. Learn more: bit.ly/3Lvy4Bo
1
2
288
Daniel A. Ermann, MD retweeted
3 Jul 2024
Check out @ErmannMD and my new article @ASCO, #ASCODailyNews on Treatment of Richter Transformation. @TischCancer
-Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring a Personalized Approach dailynews.ascopubs.org/do/ri…
5
6
12
1,073
Daniel A. Ermann, MD retweeted
14 Mar 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma ashpublications.org/blood/ar…
34
94
7,778
Daniel A. Ermann, MD retweeted
16 Oct 2023
Data on patient outcomes for individuals with #CLL who are >80 is limited due to their underrepresentation in clinical trials. This study used information from the Mayo Clinic CLL Database to analyze how this population responds to treatment for CLL. bit.ly/46xNrSz
1
2
489